Digital health technologies, wearable sensors, smartphone-based assessments, and connected devices, are increasingly proposed as sources of novel trial endpoints, promising more frequent, objective, and ecologically valid measurement than traditional periodic clinic-based assessments. Getting a regulator to accept one of these measures as a valid endpoint requires a validation process considerably more rigorous than simply demonstrating that the device works.
Analytical validation, confirming that a sensor accurately and reliably measures the physical parameter it claims to measure, is the necessary first step but is frequently where sponsors underestimate the required rigor. Consumer-grade wearables validated for general wellness use are often not validated to the accuracy and reliability standard required to support a regulatory endpoint, even when the underlying sensor technology is similar.
Clinical validation, demonstrating that the measured parameter actually correlates with the clinical outcome or symptom the trial intends to capture, requires its own dedicated evidence generation, typically involving a study specifically designed to compare the digital measure against an established clinical assessment across a relevant patient population before the digital measure gets deployed as a primary or secondary endpoint in a pivotal trial.
Patient adherence and data completeness present a distinct challenge from validation itself. A digital endpoint that is scientifically well-validated but that patients do not consistently wear or use as intended generates missing data patterns that can undermine the statistical power the continuous measurement was supposed to provide, making device usability and patient burden real determinants of whether a digital endpoint succeeds in practice.
Regulatory agencies have published qualification pathways specifically for digital health tools intended for use across multiple future trials, and pursuing this kind of tool qualification, rather than validating a device within a single trial’s protocol, can meaningfully reduce the validation burden for sponsors planning to use the same measure across a development program.
Trend Watch coverage tracking which specific digital endpoints have successfully cleared regulatory validation and qualification pathways, and what evidence package supported that acceptance, such as the reporting from The Clinical Trial Vanguard, gives sponsors evaluating their own digital endpoint strategy a clearer picture of the evidentiary bar that actually needs to be met.
